Targeting key proteins and pathways, such as Annexin A1 and BIRC3, which are upregulated in F. nucleatum-infected CRC cells, provides additional therapeutic avenues to overcome F. nucleatum-mediated chemoresistance [106,107]. This evidence concerns the gene BIRC3 and colorectal carcinoma.